Comprehensive review of clinical presentation, diagnosis, management, and prognosis of ruptured hepatocellular carcinoma

By -

 

Executive Summary

Spontaneous rupture of hepatocellular carcinoma (rHCC) represents a catastrophic, life-threatening complication occurring in 3% to 15% of patients diagnosed with hepatocellular carcinoma (HCC). Historically, the acute phase of rHCC was associated with a staggering mortality rate of 25% to 75%. While incidence remains relatively low in Western countries (<3%), it is significantly higher in Asia and Africa, reaching up to 26% in some regions.

Modern clinical management has evolved from high-risk emergency surgeries toward a multidisciplinary approach prioritizing immediate stabilization via transcatheter arterial embolization (TAE) followed by elective, staged hepatectomy. Evidence indicates that staged hepatectomy significantly improves survival outcomes compared to TAE alone or emergency surgery, with 1-year overall survival (OS) rates reaching approximately 75.6% to 83.3% in select groups. Despite these advancements, rHCC remains a leading cause of death among HCC patients, second only to tumor progression and hepatic failure.

Epidemiology and Global Incidence

The incidence of rHCC exhibits marked geographic variation, primarily driven by the prevalence of underlying risk factors and the availability of healthcare resources.

  • Regional Variations:

    • High-Incidence Regions: Asia and Africa report rates between 3% and 26%. Specific national rates include Taiwan (26%), Hong Kong (14.5%), Southern Africa (12.7%), Thailand (12.4%), and Japan (10%).

    • Low-Incidence Regions: In the United States and Western countries, the incidence remains <3%. However, rates in the U.S. have increased two- to three-fold over the last 30 years due to the prevalence of Hepatitis C (HCV) and obesity-related fatty liver disease.

  • Mortality Trends: While hospital mortality for conservative treatment is 85% to 100%, successful surgical resection can reduce mortality to as low as 0.95%. In Japan, mortality has declined from 10.0% to 6.4% due to earlier detection efforts.

Pathophysiology of Spontaneous Rupture

The exact mechanism of spontaneous rupture is not fully understood, but three primary hypotheses describe the process:

  1. Venous Congestion Hypothesis: Rapid tumor growth and subsequent necrosis predispose neovasculature to rupture. Occlusion of hepatic veins by tumor cells increases intratumoral pressure, which is further exacerbated by portal hypertension or cirrhosis, leading to hemorrhage into the subcapsular space.

  2. Small Room Hypothesis: Tumors located in smaller liver segments (e.g., segments 2, 3, or 4) or the caudate lobe are restricted by the tough liver capsule. As the tumor grows, the lack of surrounding normal parenchyma allows the increased inner pressure to split the parenchyma, causing rupture.

  3. Vascular Injury Hypothesis: Specific inflammatory changes and immune complex deposition along small artery walls lead to the degradation of type IV collagen. This weakens the vessels, making them susceptible to rupture from minor mechanical trauma or increased vascular load.

Treatment-Related Rupture

Though rare (0.4% to 1.5%), rupture can occur as a complication of Transcatheter Arterial Chemoembolization (TACE). Risk factors include large tumor size, extracapsular extension, and superficial tumor location. Additionally, antiangiogenic agents like ramucirumab (a VEGFR-2 inhibitor) and sorafenib (a multikinase inhibitor) have been linked to potential vascular dysfunction and tumor rupture.

Clinical Presentation and Diagnosis

Clinical Manifestations

The presentation of rHCC is typically acute and progresses rapidly. Key signs include:

  • Acute Abdominal Pain: The most common symptom, occurring in 66% to 100% of cases.

  • Hemorrhagic Shock: Reported in 33% to 90% of patients, characterized by dizziness, hypotension, and tachycardia.

  • Hemoperitoneum: Abdominal distension occurs in approximately 33% of cases.

  • Liver Failure: 12% to 42% of patients develop acute-phase liver failure before hospital admission.

Diagnostic Modalities

Modality

Utility and Accuracy

Key Findings

Ultrasonography (US)

Initial screening; fast but limited.

Detection of abdominal metastasis and size.

Contrast-Enhanced US (CEUS)

Real-time imaging; safe for renal failure.

Active bleeding patterns (jet-like extravasation).

Multiphase CECT

Gold Standard (75–100% accuracy).

"Enucleation sign" (peripheral mass protruding), active contrast extravasation, discontinuous liver capsule.

Hepatic Artery Angiography

Diagnostic and therapeutic.

Active contrast blush; "sentinel signs" (sentinel vessels, hypovascular areas).

MRI

Limited acute use.

Differentiating blood age (acute vs. chronic) and identifying lesion types.

Management Strategies

The primary objective of management is the correction of hypovolemic shock and the achievement of hemostasis.

1. Conservative Treatment

Reserved for patients in poor general condition, those with extensive extrahepatic metastasis, or those with stable vital signs and no active bleeding. Mortality is exceptionally high (85–100%) due to the risk of rebleeding.

2. Transcatheter Arterial Embolization (TAE/TACE)

TAE is frequently the first-line treatment for achieving immediate hemostasis, boasting a success rate of 53% to 100%.

  • Advantages: Minimally invasive, can be performed under local anesthesia, and serves as a bridge to surgery.

  • Prognostic Factors: Serum bilirubin < 3 mg/dL and a MELD score < 13 are associated with better outcomes.

  • Complications: Post-embolization syndrome (fever, nausea, elevated liver enzymes) occurs 24 to 72 hours post-procedure.

3. Hepatectomy (Surgical Resection)

Hepatectomy offers the only chance for curative treatment but requires careful patient selection based on liver function (Child-Pugh Grade A) and tumor resectability.

  • Emergent Hepatectomy: Performed in the acute setting to achieve hemostasis and tumor resection simultaneously. It carries high in-hospital mortality (16.5% to 100%).

  • Staged Hepatectomy: Involves initial stabilization via TAE/TACE followed by elective surgery (typically 7 to 42 days later). This is currently considered the ideal treatment route.

    • Timing: Resection within 8 days of rupture may reduce peritoneal dissemination and improve survival compared to later staged resections.

Treatment Outcomes Comparison

The following table summarizes outcomes from recent studies regarding various interventions:

Study

Treatment

Outcomes (1-Year OS / Median Survival)

Wang et al. (2022)

Conservative

5.5% (1-year OS) / 1 month (MST)

Wang et al. (2022)

TAE Alone

43.2% (1-year OS) / 7 months (MST)

Lee et al. (2019)

Staged Hepatectomy

83.3% (1-year OS) / 48 months (MST)

Zhou et al. (2020)

Emergent Hepatectomy

77.5% (1-year OS) / 38.1 months (MST)

Prognosis and Conclusion

The prognosis for rHCC remains the poorest among all causes of HCC-related death. If left untreated, the median survival is a mere 1.2 to 4.0 months. However, the paradigm is shifting toward multidisciplinary management.

Key Takeaways for Clinical Practice:

  • Active Surveillance: Essential for early detection and prevention of rupture.

  • Multimodal Approach: TAE/TACE for immediate stabilization followed by staged hepatic resection offers the best long-term survival benefits.

  • Need for Global Standardization: While high-resource centers report improved outcomes, there is a significant need for specialized hepatobiliary and interventional radiology training in high-incidence, low-resource regions to reduce the global burden of rHCC.